#France #Lyon #Endometriosis #Ziwig #Endotest

Scientific Validation of Ziwig Endotest®

On December 2, 2025, the reputable journal NEJM Evidence released pivotal findings detailing the validation of Ziwig’s innovative saliva-based diagnostic tool, the Endotest®, aimed at detecting endometriosis. This groundbreaking study involved a diverse group of 971 symptomatic women aged between 18 to 43 years, all participating in a prospective, independent multicenter clinical trial across 17 hospitals in France.

High-Performance Diagnosis

The primary objective of the study was to evaluate the Ziwig Endotest®, which utilizes an advanced analysis of 109 specific salivary microRNAs, a process that merges next-generation sequencing (NGS) with cutting-edge artificial intelligence techniques. Diagnostic evaluations were conducted without prior knowledge of each patient's clinical history, thus affirming the test's methodological independence and reliability.

The results were remarkable, highlighting the diagnostic performance as follows:

• - Sensitivity: 97.3%
• - Specificity: 94.1%
• - Overall Accuracy: 96.6%
• - Positive Predictive Value: 98.2%
• - Negative Predictive Value: 91.3%

This impressive data indicates that more than 96% of women tested received accurate diagnostic outcomes, establishing the Ziwig Endotest® as a consistent and trustworthy solution that maintains high performance across various demographics and clinical conditions, regardless of hormonal treatment or medication usage.

Clinical Application and Accessibility

The Ziwig Endotest® has now been integrated into standard medical practice as a part of France's national early access program aimed at breakthrough technologies, known as the Forfait Innovation. It is currently reimbursed and accessible under medical prescription across 100 hospitals nationwide. This development allows healthcare providers to prescribe the test for women aged 18 to 43 with chronic pelvic pain indicative of endometriosis, particularly in instances where imaging results are either normal or unclear.

The Endotest® not only represents a major leap in diagnostic technology but also offers a non-invasive, rapid, and accurate method for addressing a condition that affects approximately 10% of women in their reproductive years. The historical challenge of diagnosing endometriosis, which often requires patients to endure extended wait times averaging over seven years, has been significantly mitigated through this innovation.

A Milestone for Women’s Health

Yahya El Mir, the Founder and President of Ziwig, expressed his gratitude for the support from women, hospitals, and healthcare professionals during the study's process in his comment on the publication: "This publication in NEJM Evidence signifies a monumental advancement for science and the countless women affected by endometriosis. We appreciate the unwavering commitment and collaboration that made this essential innovation possible."

The validation of the Ziwig Endotest® ushers in a new era of accessible healthcare solutions, moving toward earlier, easier, and more equitable diagnostic pathways for endometriosis. For more detailed information, you can visit Ziwig's official website.